Evidence map›Paper›PMID 38116167›Full record

ArticleJournal of clinical & translational endocrinology2024

Histopathology of telomerase reverse transcriptase promoter (

Jessica O Pinto, Masha J Livhits, Michael W Yeh, Atanas Kaykov, Joshua P Klopper, Richard T Kloos, Mohammed Alshalalfa, Yangyang Hao, Jing Huang, Mayumi Endo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical & translational endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Cytologic and Surgical Correlation ofInternational journal of surgical pathology · 2026
    Article
  2. Article
  3. Pathological Diagnosis of Thyroid Nodules with Preoperatively DetectedThyroid : official journal of the American Thyroid Association · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica O PintoDepartment of Internal Medicine, University of Washington, Seattle, WA, USA.
Masha J LivhitsSection of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Michael W YehSection of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Atanas KaykovDepartment of Marketing, Veracyte, South San Francisco, CA, USA.
Joshua P KlopperDepartment of Medical Affairs, Veracyte, Inc., South San Francisco, CA. USA.
Richard T KloosDepartment of Medical Affairs, Veracyte, Inc., South San Francisco, CA. USA.
Mohammed AlshalalfaDepartment of Research and Development, Veracyte, South San Francisco, CA, USA.
Yangyang HaoDepartment of Research and Development, Veracyte, South San Francisco, CA, USA.
Jing HuangDepartment of Research and Development, Veracyte, South San Francisco, CA, USA.
Mayumi EndoDivision of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective of this study was to analyze the risk of malignancy and the histopathology of telomerase reverse transcriptase promoter Methods: A PUBMED search of molecularly tested ITN was conducted and data on Results: Twenty-six manuscripts (published between 2014 and 2022) reported on 77 Conclusion: TERT mutated ITNs have a high risk of malignancy (84 %), and the current data does not show a difference in malignancy rate between isolated

Indexed as

Indeterminate cytologyMolecular markersSystematic reviewTERTThyroid cancerThyroid nodule

Identifiers

PMID38116167
PMCPMC10727925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.